tag:blogger.com,1999:blog-8550428.post1153701999348874668..comments2024-03-28T13:38:36.788-04:00Comments on Pharma Marketing Blog: Social Media Best Practices for Pharma Are Needed, Whatever Happens at FDAVladhttp://www.blogger.com/profile/04114063498108633047noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-8550428.post-20798840388256246712009-10-29T11:58:04.054-04:002009-10-29T11:58:04.054-04:00I love pharma. Seriously. The realist in me, howev...I love pharma. Seriously. The realist in me, however, is perplexed by an industry with unparalleled expertise in legal, regulatory and advocacy development not motivated to issue its own voluntary guidelines for using social media. This isn’t a new medium, from chat rooms to Second Life to Twitter, we’re talking about years with which to study, master and then train others on “fair balanced and appropriate use of these channels.” <br /><br />As thrilled as people are by the upcoming #FDASM meeting—myself included as I’ll be attending in person—there should be shared disappointment in PhRMA, BIO, Coalition for Healthcare Communications (among others), not to mention the individual companies, for not preparing working industry guidelines for using social media.<br /><br />Would we still need the #FDASM? Most definitely. Would said working guidelines need to be revised? No doubt about it, hence the qualifier “working guidelines.” But, for a prideful industry—renowned for carving out its own destiny—to hold back on drafting good faith guidelines combines passive resistance with head in the sand avoidance. <br /><br />I hope @pharmaguy John Mack is correct and we’ll have “published draft guidelines from the FDA before the end of 2010.” Question is to the industry at large, how do we proceed until then, or will we have more of the same fiddling for the next 13 months?<br /><br />Marian Cutler<br />www.twitter.com/mariancutlerMarianCutlerhttps://www.blogger.com/profile/17097655912820762201noreply@blogger.com